Population-specific genetic variants could revolutionize personalized cardiovascular risk assessment, particularly for individuals of Indian ancestry who carry unique cholesterol-regulating mutations. Advanced molecular modeling has revealed how specific DNA changes alter the three-dimensional structure of PCSK9, a protein that normally promotes cholesterol accumulation by destroying LDL receptors.
Molecular dynamics simulations examined three loss-of-function mutations—R93C, N298D, and A511V—comparing their behavior to normal PCSK9 when bound to LDL receptors. The A511V variant, found exclusively in Indian populations, demonstrated complete abolishment of all molecular contacts with the LDL receptor, essentially rendering the cholesterol-elevating protein nonfunctional. The R93C and N298D mutations also significantly destabilized the protein complex, though less dramatically than A511V.
This computational analysis provides mechanistic insight into why certain individuals maintain lower cholesterol levels despite dietary factors that typically raise cardiovascular risk. The findings suggest that carriers of these variants, particularly A511V, may possess natural protection against hypercholesterolemia and subsequent heart disease. However, the clinical significance remains uncertain without large-scale population studies validating these protective effects in real-world cardiovascular outcomes. The research represents incremental progress in pharmacogenomics, potentially informing future cholesterol management strategies tailored to genetic backgrounds. While promising for personalized medicine approaches, translating these molecular insights into clinical practice requires extensive validation studies across diverse populations beyond computational modeling.